Enterprise Value
-149.2M
Cash
391.6M
Avg Qtr Burn
-12.55M
Short % of Float
4.05%
Insider Ownership
1.00%
Institutional Own.
94.14%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Luvelta (STRO-002) (FolRα-Targeting ADC) Details Ovarian cancer, Cancer, Endometrial cancer | Phase 2/3 Data readout | |
STRO-001 (BN301) (CD74-Targeting ADC) Details Cancer, B-cell lymphoma, Follicular lymphoma, Lymphoma, Mantle cell lymphoma | Phase 1 Data readout | |
M1231 (MUC1-EGFR Bispecific ADC) Details Solid tumor/s, Esophageal cancer, Non-small cell lung carcinoma, Cancer | Failed Discontinued |